UTERINE SARCOMAS - A REVIEW OF THE EDINBURGH EXPERIENCE FROM 1974 TO1992

被引:47
作者
TINKLER, SD [1 ]
COWIE, VJ [1 ]
机构
[1] WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND
关键词
D O I
10.1259/0007-1285-66-791-998
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A retrospective review of patients treated for a uterine sarcoma in Edinburgh from 1974 to 1992 has been performed. Clinical details at presentation, tumour pathology, treatment and the outcome of treatment were all recorded. 82 patients' case notes were reviewed. 54 patients had died and 28 were alive (mean follow-up period 80.3 months). 39 patients had a malignant mixed mesodermal tumour, 12 patients had an endometrial stromal sarcoma, and 27 had a leiomyosarcoma. Using a modified FIGO staging retrospectively, 41 patients had Stage 1 disease, two patients had Stage 2, 16 patients had Stage 3, and 13 patients had Stage 4 disease. Definitive treatment of total abdominal hysterectomy and bilateral salpingo-oophorectomy was used in 69 patients, with 35 of these patients also receiving post-operative radiotherapy to the pelvis. 13 patients did not undergo surgery. Five of these patients received radical radiotherapy, three patients received palliative radiotherapy, and five patients were not treated. The overall median survival is 15 months and the 5-year actuarial survival is 31%. 25 of the 26 surviving patients had Stage 1 disease at presentation. Post-operative pelvic radiotherapy did not influence either survival or local tumour control. 51 of the 54 patients who relapsed had evidence of distant metastases. We conclude that total abdominal hysterectomy and bilateral salpingo-oophorectomy remains the treatment of choice for uterine sarcomas.
引用
收藏
页码:998 / 1001
页数:4
相关论文
共 18 条
  • [1] Bliss P, 1992, Clin Oncol (R Coll Radiol), V4, P373, DOI 10.1016/S0936-6555(05)81130-6
  • [2] ECHT G, 1990, CANCER, V66, P35, DOI 10.1002/1097-0142(19900701)66:1<35::AID-CNCR2820660108>3.0.CO
  • [3] 2-V
  • [4] EVANS HL, 1988, CANCER-AM CANCER SOC, V62, P2239, DOI 10.1002/1097-0142(19881115)62:10<2239::AID-CNCR2820621028>3.0.CO
  • [5] 2-Y
  • [6] UTERINE SARCOMAS - PROGNOSTIC FACTORS AND TREATMENT MODALITIES - STUDY ON 209 PATIENTS
    GEORGE, M
    PEJOVIC, MH
    KRAMAR, A
    [J]. GYNECOLOGIC ONCOLOGY, 1986, 24 (01) : 58 - 67
  • [7] Kempson R L, 1970, Hum Pathol, V1, P331
  • [8] LEWIS JL, 1989, SURG MANAGEMENT SOFT, P213
  • [9] MORTEL R, 1970, OBSTET GYNECOL, V35, P468
  • [10] NORRIS HJ, 1966, OBSTET GYNECOL, V28, P57